IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3414
-0.0186 (-5.17%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia.

The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s.

Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders.

The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.

IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

IGC Pharma, Inc.
IGC Pharma logo
CountryUnited States
Founded2005
IndustryBiotechnology
SectorHealthcare
Employees70
CEORam Mukunda

Contact Details

Address:
10224 Falls Road
Potomac, Maryland 20854
United States
Phone(301) 983-0998
Websiteigcpharma.com

Stock Details

Ticker SymbolIGC
ExchangeNYSEAMERICAN
Stock TypeCommon Stock
Fiscal YearApril - March
Reporting CurrencyUSD
CIK Code0001326205
CUSIP Number45408X308
ISIN NumberUS45408X3089
Employer ID20-2760393
SIC Code2834

Key Executives

NamePosition
Ram MukundaPresident, Chief Executive Officer and Director
Claudia GrimaldiVice President, Principal Financial Officer, Chief Compliance Officer and Non-Independent Director
Benysh Qureshi Esq., M.B.A.Director of Operations
Rohit Goel CPA, M.B.A.Senior Director of Accounting and Principal Accounting Officer

Latest SEC Filings

DateTypeTitle
Jul 28, 2025EFFECTNotice of Effectiveness
Jul 18, 2025S-3Registration statement under Securities Act of 1933
Jun 27, 202510-KAnnual Report
Jun 17, 20258-KCurrent Report
Feb 14, 202510-QQuarterly Report
Nov 12, 202410-QQuarterly Report
Sep 27, 20248-KCurrent Report
Aug 27, 20248-KCurrent Report
Aug 14, 2024SC 13D/A[Amend] General statement of acquisition of beneficial ownership
Aug 9, 2024144Filing